您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Montelukast
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Montelukast
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Montelukast图片
CAS NO:158966-92-8
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品名称
MK0476 free base
产品介绍
Montelukast (MK0476 free base) 是一种有效的、选择性和具有口服活性的半胱氨酸白三烯受体 1 (CysLT1) 拮抗剂。Montelukast 可用于研究预防哮喘和肝损伤。Montelukast 在肠缺血-再灌注损伤中也具有抗氧化作用,还可以减少心脏损伤。Montelukast 减少嗜酸性粒细胞浸润到哮喘气道。Montelukast 也可用于 COVID-19 的研究。
生物活性

Montelukast (MK0476 free base) is a potent, selective and orally active antagonist ofcysteinylleukotriene receptor1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research[1][2][3][4].

IC50& Target[1]

CysLT1

 

体外研究
(In Vitro)

Montelukast (5 μM; 1 h) inhibits APAP (Acetaminophen) (HY-66005)-induced cell damage[1].
Montelukast (0.01-10 μM; 30 min) diminishes the 5-oxo-ETE–induced cell migration and modulates the activation of the plasmin-plasminogen system[3].
Montelukast (10 μM; 18 h) modulates the activation of MMP-9[3].

Cell Migration Assay[3]

Cell Line:Eosinophils
Concentration:0.01-10 μM
Incubation Time:30 min
Result:Diminished the 5-oxo-ETE–induced cell migration.

Western Blot Analysis[3]

Cell Line:Eosinophils
Concentration:10 μM
Incubation Time:18 h
Result:Reduced the 5-oxo-ETE–boosted MMP-9 secretion.
体内研究
(In Vivo)

Montelukast (3 mg/kg; oral gavage) protects against APAP-induced hepatotoxicity in mice[1].
Montelukast (1 mg/kg; miniosmotic pump administration) reduces the airway remodeling changes observed in OVA-treated mice and blocks the actions of cysteinyl leukotrienes (LT) C4, D4, and E4 mediated by the CysLT1 receptor[2].
Montelukast (1 mg/kg; miniosmotic pump administration) reduces the elevated levels of IL-4 and IL-13 found in the BAL fluid of OVA-treated mice[2].

Animal Model:C57BL/6J mice (8-week-old; 22-25 g) are induced acute hepatic injury[1]
Dosage:3 mg/kg
Administration:Oral gavage 1 h after saline or APAP administration
Result:Decreased serum levels of alanine transaminase (ALT) and aspartate aminotransferase (AST), and alleviated liver damage.
Clinical Trial
分子量

586.18

Formula

C35H36ClNO3S

CAS 号

158966-92-8

中文名称

孟鲁司特

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.